AU2002338329B2 - Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism - Google Patents

Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism Download PDF

Info

Publication number
AU2002338329B2
AU2002338329B2 AU2002338329A AU2002338329A AU2002338329B2 AU 2002338329 B2 AU2002338329 B2 AU 2002338329B2 AU 2002338329 A AU2002338329 A AU 2002338329A AU 2002338329 A AU2002338329 A AU 2002338329A AU 2002338329 B2 AU2002338329 B2 AU 2002338329B2
Authority
AU
Australia
Prior art keywords
fatty acid
composition
group
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002338329A
Other languages
English (en)
Other versions
AU2002338329C1 (en
AU2002338329A1 (en
Inventor
Fernando Rodriguez De Fonseca
Daniele Piomelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of AU2002338329C1 publication Critical patent/AU2002338329C1/en
Publication of AU2002338329A1 publication Critical patent/AU2002338329A1/en
Publication of AU2002338329B2 publication Critical patent/AU2002338329B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2002338329A 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism Ceased AU2002338329B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27954201P 2001-03-27 2001-03-27
US60/279,542 2001-03-27
US33628901P 2001-10-31 2001-10-31
US60/336,289 2001-10-31
PCT/US2002/009773 WO2002080860A2 (en) 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism

Publications (3)

Publication Number Publication Date
AU2002338329C1 AU2002338329C1 (en) 2002-10-21
AU2002338329A1 AU2002338329A1 (en) 2003-04-10
AU2002338329B2 true AU2002338329B2 (en) 2006-09-07

Family

ID=26959730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002338329A Ceased AU2002338329B2 (en) 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism

Country Status (11)

Country Link
US (3) US6911474B2 (enExample)
EP (1) EP1408945A4 (enExample)
JP (1) JP2004526745A (enExample)
KR (1) KR20030087657A (enExample)
CN (1) CN1523982A (enExample)
AU (1) AU2002338329B2 (enExample)
CA (1) CA2442683A1 (enExample)
EA (1) EA006556B1 (enExample)
IL (1) IL158131A0 (enExample)
MX (1) MXPA03008823A (enExample)
WO (1) WO2002080860A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030087657A (ko) 2001-03-27 2003-11-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 체지방 감소 및 지방산 대사 조절을 위한 방법, 화합물 및조성물
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
CA2475630C (en) 2002-02-12 2011-01-18 Hunza Di Pistolesi Elvira & C. S.A.S. N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
US20050101542A1 (en) * 2002-08-20 2005-05-12 Regents Of The University Of California Combination therapy for controlling appetites
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
WO2004045307A2 (en) * 2002-11-18 2004-06-03 Natural Asa Dietry supplements and foods product comprising oleylethanolamide
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
CA2542547A1 (en) * 2003-10-16 2005-05-26 Daniele Piomelli Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
ES2308056T3 (es) * 2004-03-06 2008-12-01 Cognis Ip Management Gmbh Uso de acidos grasos insaturados par ala reduccion del apetito o de la ingesta de alimentos.
JP2006061086A (ja) * 2004-08-27 2006-03-09 Morishita Jintan Kk 脂肪代謝改善効果を有する被験試料のスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2007006319A2 (en) * 2005-07-14 2007-01-18 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
ES2354390T3 (es) 2006-04-11 2011-03-14 Arena Pharmaceuticals, Inc. Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo.
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2009033050A1 (en) * 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth Sys Tem Of Higher Education Diagnostic and therapeutic uses of augmenter of liver regeneration in inflammatory conditions
ES2291147B1 (es) * 2007-10-15 2008-11-01 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Derivados pirazolicos de amidas de acidos grasos como activadores especificos de receptores ppar-alfa, procedimiento de preparacion y utilizacion.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
US20110165198A1 (en) * 2008-05-19 2011-07-07 Delphine Tissot-Favre Method for reducing lipid absorption by an animal
CN102791145A (zh) * 2010-03-24 2012-11-21 雀巢产品技术援助有限公司 增强可食用组合物的适口性的方法
RU2590977C2 (ru) 2010-07-02 2016-07-10 Хеликс Байомедикс, Инк. Производные n-ациламинокислот для лечения таких патологий кожи, как целлюлит
CA2824317C (en) 2011-01-19 2014-12-16 Terakine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
CA2835429A1 (en) * 2011-05-10 2012-11-15 Nestec S.A. Methods and compositions for promoting lean body mass growth
US20140134135A1 (en) * 2011-05-10 2014-05-15 Nestec Sa Methods and compositions for preserving lean body mass during weight loss
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN102579414A (zh) * 2012-01-29 2012-07-18 厦门大学 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途
WO2013160492A1 (es) * 2012-04-24 2013-10-31 Fundación Instituto Mediterráneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Imabis) Terapia combinada para el tratamiento de enfermedades metabólicas
US9221747B2 (en) 2012-04-25 2015-12-29 Iowa State University Research Foundation, Inc. Method of making fatty acid N-acylalkanolamines
CN102675141A (zh) * 2012-05-04 2012-09-19 庄信修 N-(2-羟基乙基)芥酰胺及其制备与用途
EP2892366A1 (en) 2012-09-07 2015-07-15 Nestec S.A. Oleoylethanolamide compositions
CN102824338A (zh) * 2012-09-18 2012-12-19 厦门大学 s-油酰丙醇胺在制备降血脂、防治非酒精性脂肪肝药物中的用途
KR101651448B1 (ko) 2012-11-21 2016-08-26 토포카인 쎄라퓨틱스, 인코포레이티드 체지방을 국소적으로 증가시키는 방법 및 조성물
CN103113253A (zh) * 2013-01-28 2013-05-22 国家海洋局第三海洋研究所 一种不饱和脂肪酸醇胺衍生物及其制备方法与应用
ES2498521B1 (es) * 2013-02-20 2015-08-18 Fundación Pública Andaluza Para La Investigación De Málaga En Biomedicina Y Salud (Fimabis) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
NO2753788T3 (enExample) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
PH12018000077B1 (en) 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
SG10201807034XA (en) 2017-09-05 2019-04-29 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
WO2024124172A1 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for stimulating and/or enhancing exercise motivation and/or physical performance

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506224A (en) * 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
US5602164A (en) * 1992-04-28 1997-02-11 Senyorina Ltd. Anti-obesity drugs
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
WO1999060987A2 (en) * 1998-05-29 1999-12-02 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505569D0 (sv) * 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
US5679667A (en) * 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
US5554646A (en) * 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5631297A (en) 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
IT1274783B (it) * 1994-12-15 1997-07-24 Antonio Picarelli Preparato per il trattamento dell'obesita'
CA2215387A1 (en) 1995-03-20 1996-09-26 Michael R. Briggs Modulators of ob gene and screening methods therefor
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
ES2217392T3 (es) 1996-02-02 2004-11-01 MERCK & CO., INC. Agentes antidiabeticos.
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US6090836A (en) 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5803916A (en) 1996-03-19 1998-09-08 Vital-Tech Ltd. Body and joints massage device
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US6359010B1 (en) 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6974568B2 (en) 2000-05-23 2005-12-13 The Regents Of The University Of California Treatment for cough
KR20030087657A (ko) 2001-03-27 2003-11-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 체지방 감소 및 지방산 대사 조절을 위한 방법, 화합물 및조성물
US7048941B2 (en) 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
US7705039B2 (en) * 2001-04-06 2010-04-27 The Board Of Trustees Of The University Of Illinois Method for treating sleep apnea
US7351874B2 (en) * 2001-07-31 2008-04-01 The Scripps Research Institute Mouse model for fatty acid amide-related neurobehaviors
AU2003210824A1 (en) 2002-02-08 2003-09-02 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
WO2004045307A2 (en) 2002-11-18 2004-06-03 Natural Asa Dietry supplements and foods product comprising oleylethanolamide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506224A (en) * 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
US5602164A (en) * 1992-04-28 1997-02-11 Senyorina Ltd. Anti-obesity drugs
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
WO1999060987A2 (en) * 1998-05-29 1999-12-02 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochemical Pharmacology. Vol: 22, No: 20, 1973. pages 2529-36. *

Also Published As

Publication number Publication date
EA200301057A1 (ru) 2004-04-29
US20050187254A1 (en) 2005-08-25
US6911474B2 (en) 2005-06-28
EP1408945A2 (en) 2004-04-21
MXPA03008823A (es) 2004-08-12
WO2002080860A2 (en) 2002-10-17
CA2442683A1 (en) 2002-10-17
US20090005447A1 (en) 2009-01-01
EP1408945A4 (en) 2005-07-06
US7423066B2 (en) 2008-09-09
IL158131A0 (en) 2004-03-28
AU2002338329C1 (en) 2002-10-21
US20030018081A1 (en) 2003-01-23
EA006556B1 (ru) 2006-02-24
CN1523982A (zh) 2004-08-25
WO2002080860A3 (en) 2004-02-26
KR20030087657A (ko) 2003-11-14
JP2004526745A (ja) 2004-09-02

Similar Documents

Publication Publication Date Title
AU2002338329C1 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
AU2002338329A1 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
US20050154064A1 (en) Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
US20050101542A1 (en) Combination therapy for controlling appetites
EP3138415B1 (en) Metabolic imprinting effects of specifically designed lipid component
ES2660416T3 (es) Mezcla de lípidos para la nutrición de bebés
BRPI0910184B1 (pt) Preparação compreendendo uma mistura derivada de não mamíferos de conjugados de glicerofosfolipídio de soro, uso de uma preparação, e composição nutricional, farmacêutica ou nutracêutica ou alimento funcional
BRPI0415744B1 (pt) uso de uma preparação lipídica contendo ácidos graxos ômega-3 e ômega-6, esta preparação, uso de glicerofosfolipídios, composição nutracêutica e artigo alimentar funcional
US11458141B2 (en) Aryl hydrocarbon receptor (AhR) agonists for the prevention and treatment of inflammatory disorders
BR112019010607A2 (pt) uso de precursores de nad para melhorar a saúde materna e/ou saúde da prole
ES2659763T3 (es) Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
US20050054730A1 (en) Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
TW201524372A (zh) 用於提升認知能力的方法及組合物
CA3135674A1 (en) Dietary butyrate
JP7655224B2 (ja) 筋質向上剤
JP6291058B2 (ja) セリングリセロリン脂質調製物及び発作の治療方法
JP2022188235A (ja) 環状プラスメニルエタノールアミン
WO2019228994A1 (en) Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses
Matsuura et al. N-(4-hydroxyphenyl)-retinamide increases lecithin: retinol acyltransferase activity in rat liver
BR112019012741A2 (pt) composição, formulação, método para prevenir e/ou tratar caquexia em um indivíduo, uso da composição, e, produto de uso médico especial, produto de alimentos para uso específico de saúde, produto para alimentos para fins médicos especiais, produto de alimento para uso dietético especial, produto de nutrição médica e produto de alimento médico.
KR20010051509A (ko) 아포지단백질 비 분비/미소체 삼중글리세라이드 전이단백질 저해제의 용도
UA77627C2 (en) Method (variants) and composition (variants) for reducing body weight and modulating body lipid metabolism in mammals
WO2005002524A2 (en) COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα
KR20250133322A (ko) 우롤리틴과 케톤체의 조합물
Gibson Fumaric acid esters

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 MAR 2007.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 MAR

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired